Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials

Bibliography

• Jablensky A. Schizophrenia: recent epidemiologic issues. Epidemiol Rev 1995;17:10-20
   PubMed Web of Science ®Google Scholar
• WHO, The WHO world health report 2001. Mental Health: New understanding, new hope, Geneva: 2001
   Google Scholar
• Van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-45
   PubMed Web of Science ®Google Scholar
• Carlsson A. Does dopamine play a role in schizophrenia? Psychol Med 1977;7:583-97
   PubMed Web of Science ®Google Scholar
• Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978;135:165-73
   PubMedGoogle Scholar
• Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3 methoxytyramine and normetanephrine in mouse brain Acta Pharmacol Toxicol (Copenh) 1963;20:140-4
   Google Scholar
• Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-3
   PubMed Web of Science ®Google Scholar
• Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188:1217-19
   PubMed Web of Science ®Google Scholar
• Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-19
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91:415-33
   PubMed Web of Science ®Google Scholar
• Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 1976;133:197-202
   PubMed Web of Science ®Google Scholar
• Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-86
   PubMed Web of Science ®Google Scholar
• Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980;286:74-6
   PubMed Web of Science ®Google Scholar
• Kling AS, Metter EJ, Riege WH, et al. Comparison of PET measurement of local brain glucose metabolism and CAT measurement of brain atrophy in chronic schizophrenia and depression. Am J Psychiatry 1986;143:175-80
   PubMed Web of Science ®Google Scholar
• Wolkin A, Jaeger J, Brodie JD, et al. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 1985;142:564-71
   PubMed Web of Science ®Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull 2009;35:549-62
   PubMed Web of Science ®Google Scholar
• Lopez-Munoz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 2005;17:113-35
   PubMedGoogle Scholar
• Deniker P. The neuroleptics: a historical survey. Acta Physiol Scand 1990;82:83-7
   Google Scholar
• Weisel FA. Neuroleptic treatment of patients with schizophrenia: mechanisms of action and clinical significance. Br J Psychiatry 1994;164(Suppl 23):65-70
   Google Scholar
• Bitter I, Volavka J, Scheurer J. The concept of the neuroleptic threshold: an update. J Clin Psychopharmacol 1991;11:28-33
   PubMed Web of Science ®Google Scholar
• Hippius H. The history of clozapine. Psychopharmacology (Berl) 1989;99(Suppl):S3-5
   PubMedGoogle Scholar
• Matz R, Rick W, Thompson H, et al. Clozapine–a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res Clin Exp 1974;16:687-95
   PubMed Web of Science ®Google Scholar
• Svensson TH, Mathe JM, Andersson JL, et al. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]. J Clin Psychopharmacol 1995;15:11S-8S
   PubMed Web of Science ®Google Scholar
• Olney JW, Farber NB. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry 1994;55(Suppl B):43-6
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25:390-2
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-83
   PubMed Web of Science ®Google Scholar
• Szabo ST, Gould TD, Manji HK. Neurotransmitters, receptors, signal transduction, and second messengers in psychiatric disorders. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. American Psychiatric Publishing, Arlington, VA; 2009
   Google Scholar
• Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 2007;78:1-39
   PubMed Web of Science ®Google Scholar
• Joyce JN, Meador-Woodruff JH. Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology 1997;16:375-84
   PubMed Web of Science ®Google Scholar
• Lahti RA, Roberts RC, Cochrane EV, et al. Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study. Mol Psychiatry 1998;3:528-33
   PubMed Web of Science ®Google Scholar
• Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994;91:11651-4
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-71
   PubMed Web of Science ®Google Scholar
• Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009;66:13-20
   PubMed Web of Science ®Google Scholar
• McGowan S, Lawrence AD, Sales T, et al. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 2004;61:134-42
   Google Scholar
• Nozaki S, Kato M, Takano H, et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res 2009;108:78-84
   PubMed Web of Science ®Google Scholar
• Elkashef AM, Doudet D, Bryant T, et al. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 2000;100:1-11
   PubMed Web of Science ®Google Scholar
• Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 1997;23:167-74
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998;155:761-7
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996;93:9235-40
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, Gil R, et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;46:56-72
   PubMed Web of Science ®Google Scholar
• Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010;67:231-9
   PubMed Web of Science ®Google Scholar
• Laruelle M, D'Souza CD, Baldwin RM, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997;17:162-74
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000;97:8104-9
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, van de Giessen E, Slifstein M, et al. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 2009;65:1091-3
   PubMed Web of Science ®Google Scholar
• Laakso A, Bergman J, Haaparanta M, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 2001;52:115-20
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, van Dyck C, et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 2000;47:371-9
   PubMed Web of Science ®Google Scholar
• Hsiao MC, Lin KJ, Liu CY, et al. Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr Res 2003;65:39-46
   PubMed Web of Science ®Google Scholar
• Lavalaye J, Linszen DH, Booij J, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res 2001;47:59-67
   PubMed Web of Science ®Google Scholar
• Schmitt GJ, Meisenzahl EM, Frodl T, et al. The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand [99mTc] TRODAT-1. J Psychopharmacol 2005;19:488-93
   PubMed Web of Science ®Google Scholar
• Mateos JJ, Lomena F, Parellada E, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl) 2007;191:805-11
   PubMed Web of Science ®Google Scholar
• Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012;69:776-86
   PubMed Web of Science ®Google Scholar
• Zakzanis KK, Hansen KT. Dopamine D2 densities and the schizophrenic brain. Schizophr Res 1998;32:201-6
   PubMed Web of Science ®Google Scholar
• Kestler LP, Walker E, Vega EM. Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav Pharmacol 2001;12:355-71
   PubMed Web of Science ®Google Scholar
• Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998;42:211-21
   PubMedGoogle Scholar
• Graff-Guerrero A, Mamo D, Shammi CM, et al. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch Gen Psychiatry 2009;66:606-15
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002;22:3708-19
   PubMed Web of Science ®Google Scholar
• Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997;385:634-6
   PubMed Web of Science ®Google Scholar
• Hirvonen J, van Erp TG, Huttunen J, et al. Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry 2006;163:1747-53
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Czudek C. Status of the dopaminergic system in post-mortem brain in schizophrenia. Psychopharmacol Bull 1988;24:345-7
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Riederer P, Jellinger K, et al. Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacology 1981;20:1319-20
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Riederer P, Reynolds GP, et al. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 1989;75:1-10
   PubMed Web of Science ®Google Scholar
• Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977;196:326-8
   PubMed Web of Science ®Google Scholar
• Gurevich EV, Bordelon Y, Shapiro RM, et al. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997;54:225-32
   PubMed Web of Science ®Google Scholar
• Marzella PL, Hill C, Keks N, et al. The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia. Biol Psychiatry 1997;42:648-54
   PubMed Web of Science ®Google Scholar
• Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441-5
   PubMed Web of Science ®Google Scholar
• Huttunen J, Heinimaa M, Svirskis T, et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry 2008;63:114-17
   PubMed Web of Science ®Google Scholar
• Howes O, Bose S, Turkheimer F, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 2011;16:885-6
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Stokes PR, Owens SF, et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med 2011;41:2331-8
   PubMed Web of Science ®Google Scholar
• Mizrahi R, Addington J, Rusjan PM, et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 2012;71:561-7
   PubMed Web of Science ®Google Scholar
• Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005;62:975-83
   PubMed Web of Science ®Google Scholar
• Henry LP, Amminger GP, Harris MG, et al. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. J Clin Psychiatry 2010;71:716-28
   PubMed Web of Science ®Google Scholar
• Poulton R, Caspi A, Moffitt TE, et al. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 2000;57:1053-8
   PubMed Web of Science ®Google Scholar
• Diagnostic and statistical manual of mental disorders. 4th editon. American Psychiatric Association, Washington, DC; 2000
   Google Scholar
• American Psychiatric Association Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982;39:789-94
   PubMed Web of Science ®Google Scholar
• Crow TJ. The two-syndrome concept: origins and current status. Schizophr Bull 1985;11:471-86
   PubMed Web of Science ®Google Scholar
• Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-83
   PubMed Web of Science ®Google Scholar
• Cohen AS, Saperstein AM, Gold JM, et al. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 2007;33:1201-12
   PubMed Web of Science ®Google Scholar
• Szoke A, Trandafir A, Dupont ME, et al. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 2008;192:248-57
   PubMed Web of Science ®Google Scholar
• Dibben CR, Rice C, Laws K, et al. Is executive impairment associated with schizophrenic syndromes? A meta-analysis. Psychol Med 2009;39:381-92
   PubMed Web of Science ®Google Scholar
• Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry 2008;165:579-87
   PubMed Web of Science ®Google Scholar
• Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 2007;64:532-42
   PubMed Web of Science ®Google Scholar
• Henry JD, Crawford JR. A meta-analytic review of verbal fluency deficits in schizophrenia relative to other neurocognitive deficits. Cogn Neuropsychiatry 2005;10:1-33
   PubMedGoogle Scholar
• Laws KR. A meta-analytic review of Wisconsin Card Sort studies in schizophrenia: general intellectual deficit in disguise? Cogn Neuropsychiatry 1999;4:1-30. discussion 1-5
   PubMedGoogle Scholar
• Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-45
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321
   PubMed Web of Science ®Google Scholar
• Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26:119-36
   PubMed Web of Science ®Google Scholar
• Bryson G, Bell MD. Initial and final work performance in schizophrenia: cognitive and symptom predictors. J Nerv Ment Dis 2003;191:87-92
   PubMed Web of Science ®Google Scholar
• Ventura J, Hellemann GS, Thames AD, et al. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res 2009;113:189-99
   PubMed Web of Science ®Google Scholar
• Shamsi S, Lau A, Lencz T, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res 2011;126:257-64
   PubMed Web of Science ®Google Scholar
• Harvey PD, Koren D, Reichenberg A, et al. Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull 2006;32:250-8
   PubMed Web of Science ®Google Scholar
• Bell MD, Mishara AL. Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments. Schizophr Res 2006;81:17-27
   PubMed Web of Science ®Google Scholar
• Brozoski TJ, Brown RM, Rosvold HE, et al. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979;205:929-32
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Cai JX, Murphy BL, et al. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 1994;116:143-51
   PubMed Web of Science ®Google Scholar
• Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci 2004;5:483-94
   PubMed Web of Science ®Google Scholar
• Salamone JD, Correa M, Farrar A, et al. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl) 2007;191:461-82
   PubMed Web of Science ®Google Scholar
• Salamone JD. Functions of mesolimbic dopamine: changing concepts and shifting paradigms. Psychopharmacology (Berl) 2007;191:389
   Web of Science ®Google Scholar
• Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-9
   PubMed Web of Science ®Google Scholar
• Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992;32:1-17
   PubMed Web of Science ®Google Scholar
• Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998;28:309-69
   PubMed Web of Science ®Google Scholar
• Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007;191:391-431
   PubMed Web of Science ®Google Scholar
• Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009;8:1128-39
   PubMed Web of Science ®Google Scholar
• Gotham AM, Brown RG, Marsden CD. ‘Frontal' cognitive function in patients with Parkinson's disease ‘on' and ‘off' levodopa. Brain 1988;111(Pt 2):299-321
   PubMed Web of Science ®Google Scholar
• Auriel E, Hausdorff JM, Herman T, et al. Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study. Clin Neuropharmacol 2006;29:15-17
   PubMed Web of Science ®Google Scholar
• Jubault T, Monetta L, Strafella AP, et al. L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network. PLoS One 2009;4:e6154
   PubMed Web of Science ®Google Scholar
• Callicott JH, Egan MF, Mattay VS, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 2003;160:709-19
   PubMed Web of Science ®Google Scholar
• Callicott JH, Mattay VS, Bertolino A, et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex 1999;9:20-6
   PubMed Web of Science ®Google Scholar
• Callicott JH, Mattay VS, Verchinski BA, et al. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry 2003;160:2209-15
   PubMed Web of Science ®Google Scholar
• Braus DF, Weber-Fahr W, Tost H, et al. Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2002;59:696-701
   PubMed Web of Science ®Google Scholar
• Curtis VA, Bullmore ET, Morris RG, et al. Attenuated frontal activation in schizophrenia may be task dependent. Schizophr Res 1999;37:35-44
   PubMed Web of Science ®Google Scholar
• Fuentes LJ. Selective attention deficit in schizophrenia. Rev Neurol 2001;32:387-91
   PubMed Web of Science ®Google Scholar
• Ford JM, Gray M, Whitfield SL, et al. Acquiring and inhibiting prepotent responses in schizophrenia: event-related brain potentials and functional magnetic resonance imaging. Arch Gen Psychiatry 2004;61:119-29
   PubMed Web of Science ®Google Scholar
• Harvey PD, Bowie CR, Friedman JI. Cognition in schizophrenia. Curr Psychiatry Rep 2001;3:423-8
   PubMedGoogle Scholar
• Hazlett EA, Buchsbaum MS, Haznedar MM, et al. Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology 1998;35:186-98
   PubMed Web of Science ®Google Scholar
• Kiehl KA, Liddle PF. An event-related functional magnetic resonance imaging study of an auditory oddball task in schizophrenia. Schizophr Res 2001;48:159-71
   PubMed Web of Science ®Google Scholar
• MacDonald AW III, Carter CS. Event-related FMRI study of context processing in dorsolateral prefrontal cortex of patients with schizophrenia. J Abnorm Psychol 2003;112:689-97
   PubMed Web of Science ®Google Scholar
• Perlstein WM, Dixit NK, Carter CS, et al. Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. Biol Psychiatry 2003;53:25-38
   PubMed Web of Science ®Google Scholar
• Salgado-Pineda P, Baeza I, Perez-Gomez M, et al. Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients. Neuroimage 2003;19:365-75
   PubMed Web of Science ®Google Scholar
• Silberstein RB, Line P, Pipingas A, et al. Steady-state visually evoked potential topography during the continuous performance task in normal controls and schizophrenia. Clin Neurophysiol 2000;111:850-7
   PubMed Web of Science ®Google Scholar
• Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006;67(Suppl 9):9-13; discussion 36-42
   PubMedGoogle Scholar
• Volz H, Gaser C, Hager F, et al. Decreased frontal activation in schizophrenics during stimulation with the continuous performance test – a functional magnetic resonance imaging study. Eur Psychiatry 1999;14:17-24
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Xu X, Thompson JL, et al. Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112. J Psychopharmacol 2012;26:794-805
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Simpson N, Kegeles L, et al. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse 1999;32:93
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A. Recent evidence for dopamine abnormalities in schizophrenia. Eur Psychiatry 2002;17:341-7
   Web of Science ®Google Scholar
• Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004;7(Suppl 1):S1-5
   PubMed Web of Science ®Google Scholar
• Goto Y, Grace AA. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective. Int Rev Neurobiol 2007;78:41-68
   PubMed Web of Science ®Google Scholar
• Lipkovich IA, Deberdt W, Csernansky JG, et al. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry 2009;9:44
   PubMedGoogle Scholar
• Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007;89:211-24
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-25
   PubMed Web of Science ®Google Scholar
• Green MF, Marshall BD Jr, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804
   PubMed Web of Science ®Google Scholar
• Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-22
   PubMed Web of Science ®Google Scholar
• Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004;161:985-95
   PubMed Web of Science ®Google Scholar
• Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64:633-47
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301-7
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32:214-19
   PubMed Web of Science ®Google Scholar
• Marder SR. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci 2006;8:109-13
   PubMedGoogle Scholar
• Kirkpatrick B, Kopelowicz A, Buchanan RW, et al. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 2000;22:303-10
   PubMed Web of Science ®Google Scholar
• Laughren T, Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull 2006;32:220-2
   PubMed Web of Science ®Google Scholar
• Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr Bull 2006;32:225-30
   PubMed Web of Science ®Google Scholar
• Childress AC, Sallee FR. The use of lisdexamfetamine dimesylate for the treatment of ADHD. Expert Rev Neurother 2012;12:13-26
   PubMed Web of Science ®Google Scholar
• Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010;6:317-27
   PubMed Web of Science ®Google Scholar
• Lasser R, Dirks B, Nasrallah H, et al. Poster #175 adjunctive lisdexamfetamine dimesylate treatmentof predominant negative symptoms of schizophrenia in clinically stable adults maintained on atypical antipsychotic agents: a 14-week trial. Schizophr Res 2012;136(Suppl 1):S248-S9
   Google Scholar
• Tunbridge EM, Bannerman DM, Sharp T, et al. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 2004;24:5331-5
   PubMed Web of Science ®Google Scholar
• Farrell SM, Tunbridge EM, Braeutigam S, et al. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry 2012;71:538-44
   PubMed Web of Science ®Google Scholar
• Roussos P, Giakoumaki SG, Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol Psychiatry 2009;66:997-1004
   PubMed Web of Science ®Google Scholar
• Gupta M, Kaur H, Jajodia A, et al. Diverse facets of COMT: from a plausible predictive marker to a potential drug target for schizophrenia. Curr Mol Med 2011;11:732-43
   PubMed Web of Science ®Google Scholar
• Jaskiw GE, Popli AP. A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications. Psychopharmacology (Berl) 2004;171:365-74
   PubMed Web of Science ®Google Scholar
• Healy D. The Creation of psychopharmacology. Harvard University Press, Cambridge, MA: 2002
   Google Scholar
• Lingjaerde O. Tetrabenazine (Nitoman) in the treatment of psychoses. with a discussion on the central mode of action of tetrabenazine and reserpine. Acta Psychiatr Scand 1963;39(Suppl 170):1-09
   PubMedGoogle Scholar
• NBI-98854 - Vesicular Monoamine Transporter 2 Inhibitor (VMAT2). Available from: http://www.neurocrine.com/index.cfm?navId=83 [Last accessed 5 April 2013]
   Google Scholar
• McClure MM, Harvey PD, Goodman M, et al. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology 2010;35:1356-62
   PubMed Web of Science ®Google Scholar
• Lei G, Anastasio NC, Fu Y, et al. Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength. J Neurochem 2009;109:1017-30
   PubMed Web of Science ®Google Scholar
• George MS, Molnar CE, Grenesko EL, et al. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 2007;93:42-50
   PubMed Web of Science ®Google Scholar
• Grunder G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs 2010;11:823-32
   PubMed Web of Science ®Google Scholar
• Bose A, Li D, Migliore R, et al. P03-185 - the efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Eur Psychiatry 2011;26(Suppl 1):1354
   Google Scholar
• Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013;9:193-206
   PubMed Web of Science ®Google Scholar
• Yang K, Jin G, Wu J. The neuropharmacology of (-)-stepholidine and its potential applications. Curr Neuropharmacol 2007;5:289-94
   PubMed Web of Science ®Google Scholar
• Natesan S, Reckless GE, Barlow KB, et al. The antipsychotic potential of l-stepholidine–a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology (Berl) 2008;199:275-89
   PubMed Web of Science ®Google Scholar
• Schmidt ME, Kent JM, Daly E, et al. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia. Eur Neuropsychopharmacol 2012;22:721-33
   PubMed Web of Science ®Google Scholar
• Millan MJ, Svenningsson P, Ashby CR Jr, et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther 2008;324(2):600-11
   PubMed Web of Science ®Google Scholar
• Millan MJ, Buccafusco JJ, Loiseau F, et al. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol 2010;13:1035-51
   PubMed Web of Science ®Google Scholar
• Redden L, Rendenbach-Mueller B, Abi-Saab WM, et al. A double-blind, randomized, placebo-controlled study of the dopamine D(3) receptor antagonist ABT-925 in patients with acute schizophrenia. 2011;31(2):221-5
   Google Scholar
• Casey DE, Sands EE, Heisterberg J, et al. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 2008;200:317-31
   PubMed Web of Science ®Google Scholar
• Vanover KE, Snyder GL, Hendrick JP, et al. ITI-007: a novel therapy for the treatment of schizophrenia and related psychoses. Schizophr Res 2010;117:504
   Web of Science ®Google Scholar
• The clinical phase III programme commenced on zicronapine. Available from: http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608573 [Last accessed 05 April 2013]
   Google Scholar
• Geffen Y, Keefe R, Rabinowitz J, et al. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry 2012;73:e1168-74
   PubMedGoogle Scholar
• Catafau AM, Bullich S, Nucci G, et al. Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812. J Nucl Med 2011;52:526-34
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S. Antipsychotic dosing: how much but also HoW OFTEN? Schizophr Bull 2010;36:900-3
   PubMed Web of Science ®Google Scholar
• Remington G. Augmenting clozapine response in treatment-resistant schizophrenia. In: Elkis H, Meltzer HY, editor. Therapy-resistant schizophrenia. Karger, Basel: 2010. p. 129-51
   Google Scholar
• Remington G. Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target. J Psychiatry Neurosci 2003;28:275-84
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S, Foussias G, et al. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012;32:95-9
   PubMed Web of Science ®Google Scholar
• Miller R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. Curr Neuropharmacol 2009;7:315-30
   PubMed Web of Science ®Google Scholar
• Miller R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: part I. Curr Neuropharmacol 2009;7:302-14
   PubMed Web of Science ®Google Scholar
• Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull 2009;35:300-6
   PubMed Web of Science ®Google Scholar
• Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiatr Serv 2005;56:735-42
   PubMed Web of Science ®Google Scholar
• Jackson JH. Selected writings. Basic Books, New York, NY; 1958
   Google Scholar
• Dickson H, Laurens KR, Cullen AE, et al. Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia. Psychol Med 2011;1-13
   Google Scholar
• Fusar-Poli P, DesteG, et al. Cognitive functioning in prodromal psychosis: a meta-analysis cognitive functioning in prodromal psychosis. Arch Gen Psychiatry 2012;69:562-71
   PubMed Web of Science ®Google Scholar
• Yung AR. Identification and treatment of the prodromal phase of psychotic disorders: perspectives from the PACE Clinic. Early Interv Psychiatry 2007;1:224-35
   Web of Science ®Google Scholar
• Remington G, Kapur S. Antipsychotic dosing: how much but also how often? Schizophr Bull 2010;36(5):900-3
   PubMed Web of Science ®Google Scholar
• Seeman P, Remington G. Antipsychotic dosing: extended, and transient. Clin Schizophr Relat Psychoses 2012;6:86-7
   PubMedGoogle Scholar
• Boonstra G, Burger H, Grobbee DE, et al. Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int J Psychiatry Clin Pract 2011;15:128-34
   PubMed Web of Science ®Google Scholar
• Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158:1835-42
   PubMed Web of Science ®Google Scholar